ISRCTN11400592终止未知
Sustainable Community-wide Active case finding for Lung hEalth
ondon School of Hygiene & Tropical Medicine0 个研究点目标入组 78,400 人开始时间: 2019年5月7日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 终止
- 发起方
- 入组人数
- 78,400
研究概览
简要总结
2023 Results article in https://pubmed.ncbi.nlm.nih.gov/38051717/ (added 07/12/2023)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •For the ACF intervention:
- •1. Aged 18 years or older
- •2. Resident of an intervention cluster
- •3. Reported cough for 2 weeks or longer
- •4. Willing to provide sputum for TB testing following information provided in lieu of informed consent.
- •For the post-intervention TB disease prevalence surveys:
- •1. Aged 18 years or older
- •2. Resident of an intervention or non-intervention cluster
- •3. Intending to remain within Blantyre City for at least the next 8 weeks
- •4. Willing to have radiological screening for TB (with abdominal screening for women of child bearing age)
- •For the post-intervention Skin Test Survey:
- •1. Aged less than 3 years
- •2. Resident of an intervention or non-intervention cluster
- •3. Available for reading of results 48 to 72 hours after skin test placement
排除标准
- •ACF participants:
- •1. Not currently on TB treatment
研究者
相似试验
进行中（未招募）
1 期
An open label, long-term extension study to determine how safe and tolerable oral Dersimelagon is in subjects with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)MedDRA version: 24.0Level: LLTClassification code: 10015289Term: Erythropoietic protoporphyria Class: 10010331CTIS2024-514466-38-00Mitsubishi Tanabe Pharma America Inc.151
进行中（未招募）
1 期
An open label, long-term extension study to determine how safe and tolerable oral Dersimelagon is in subjects with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)Erythropoietic Protoporphyria or X-Linked ProtoporphyriaMedDRA version: 24.0Level: LLTClassification code 10015289Term: Erythropoietic protoporphyriaSystem Organ Class: 100000004850EUCTR2021-001831-17-SEMitsubishi Tanabe Pharma Development America, Inc.184
进行中（未招募）
1 期
An open label, long-term extension study to determine how safe and tolerable oral Dersimelagon is in subjects with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)Erythropoietic Protoporphyria or X-Linked ProtoporphyriaMedDRA version: 24.0Level: LLTClassification code 10015289Term: Erythropoietic protoporphyriaSystem Organ Class: 100000004850EUCTR2021-001831-17-ESMitsubishi Tanabe Pharma Development America (MTDA), Inc.184
进行中（未招募）
3 期
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)JPRN-jRCT2041210146Kondou Kazuoki151
进行中（未招募）
1 期
An open label, long-term extension study to determine how safe and tolerable oral Dersimelagon is in subjects with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)Erythropoietic Protoporphyria or X-Linked ProtoporphyriaMedDRA version: 24.0Level: LLTClassification code 10015289Term: Erythropoietic protoporphyriaSystem Organ Class: 100000004850EUCTR2021-001831-17-DEMitsubishi Tanabe Pharma Development America (MTDA), Inc.184